| Combination of | |
|---|---|
| Leuprorelin | Gonadotropin-releasing hormone agonist |
| Norethisterone acetate | Progestin |
| Clinical data | |
| Trade names | Lupaneta Pack |
| Other names | Leuprolide/norethindrone acetate |
| AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
|
Routes of administration | Intramuscular and by mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
Leuprorelin/norethisterone acetate, also known as leuprolide/norethindrone acetate and sold under the brand name Lupaneta Pack, is a co-packaged medication used to treat endometriosis. [1] It contains leuprorelin as the acetate, a gonadotropin-releasing hormone agonist, and norethisterone acetate, a progestin. [1] The leuprorelin is given by intramuscular injection and the norethisterone acetate is taken by mouth. [1]
The co-packaged medication was approved for medical use in the United States in December 2012. [2]
Medical uses
Leuprorelin/norethisterone acetate is indicated for the initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. [1]
References
- ^ a b c d e "Lupaneta Pack (leuprolide acetate for depot suspension; norethindrone acetate tablets), co-packaged for intramuscular use and for oral use, respectively Initial U.S. Approval: 2012". DailyMed. Archived from the original on 2 February 2023. Retrieved 1 February 2023.
- ^ "Drug Approval Package: Lupaneta Pack (leuprolide acetate for depot suspension and norethindrone acetate) NDA #203696". U.S. Food and Drug Administration (FDA). 9 September 2013. Archived from the original on 5 April 2021. Retrieved 1 February 2023.
Further reading
- Surrey ES (2022). "GnRH agonists in the treatment of symptomatic endometriosis: a review". F&S Reports. 4 (2): 40–45. doi: 10.1016/j.xfre.2022.11.009. PMC 10201290. PMID 37223763.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |